A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up

Journal:

Blood

Published:

2025-07-31

DOI:

10.1182/blood.2024027681

Affiliations:

7

Authors:

22

Go to article

Institutions	Authors	Share
Fred Hutchinson Cancer Center, United States of America (USA)	13.400000 13.400000	0.61
University of Washington (UW), United States of America (USA)	4.616667	0.21
Juno Therapeutics, Inc., United States of America (USA)	3.250000	0.15
Sylvester Comprehensive Cancer Center (Sylvester), UM, United States of America (USA)	0.533333	0.02
University of Miami (UM), United States of America (USA)	0.200000	0.01

Interested in Oncology and Carcinogenesis?